Sorrento Therapeutics Mexico to Partner with the World Boxing Council for the Screening of COVID-19 of all Convention Attendees with COVI-STIX at the 59th World Boxing Council Convention in Mexico City
The pandemic brought the world to a standstill and while most sports froze, boxing remained active through efforts by promoters, boxing commissions and the WBC. Boxing leads the world of sports in administrative and medical protocols to allow boxing matches to be held in bubbles without fans present.
Testing is and should remain a major factor for the successful organization of any public event, including boxing events with audiences present at maximum capacity.
Sorrento Therapeutics Mexico has teamed with the WBC to provide COVI-STIX rapid testing for the event and have together committed to be very active in providing solutions to the boxing industry, as well as other sports and entertainment focused events.
COVI-STIX tests will be administered to all convention attendees prior to registration and a local testing laboratory will provide testing and travel certificates to all foreign visitors requiring proof of testing for international travel.
Many superstars will be in
For information regarding the WBC convention, please refer to WBC’s website at https://wbcboxing.com/en/info-about-wbc-convention-59/ or send an email to firstname.lastname@example.org.
Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates (“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVIGUARD™, COVI-AMG™, COVISHIELD™, COVI-MSC™ and COVIDROPS™; and diagnostic test solutions, including COVITRACK™, COVISTIX™ and COVITRACE™.
Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on
For more information visit www.sorrentotherapeutics.com.
The annual convention unites delegates from all member-countries and key boxers from all over the world. During the convention, participants discuss topical issues, plans and future fights. Current champions often find out their rivals and the candidates for the championship title.
Rules are reviewed and grievances are heard. The convention deals with the previous 12 months and the next 12 months and all the issues of the day are heard and discussed during open sessions in a transparent and democratic process.
For more information, visit www.wbcboxing.com.
This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to
Media and Investor Relations Contact
Sorrento® and the Sorrento logo are registered trademarks of
G-MAB™, DAR-T™, SOFUSA™, COVIGUARD™, COVI-AMG™, COVISHIELD™, COVIDROPS™, COVI-MSC™, COVITRACK™, COVITRACE™ and COVI-STIX™ are trademarks of
SEMDEXA™ is a trademark of
ZTlido® is a registered trademark owned by
All other trademarks are the property of their respective owners.
Source: Sorrento Therapeutics, Inc.